| Literature DB >> 33335152 |
Amir Seyedsalehi1,2,3,4, Leila Daneshmandi1,2,3,4, Mohammed Barajaa1,2,3,4, John Riordan1,2,3, Cato T Laurencin5,6,7,8,9,10,11.
Abstract
The ability to produce constructs with a high control over the bulk geometry and internal architecture has situated 3D printing as an attractive fabrication technique for scaffolds. Various designs and inks are actively investigated to prepare scaffolds for different tissues. In this work, we prepared 3D printed composite scaffolds comprising polycaprolactone (PCL) and various amounts of reduced graphene oxide (rGO) at 0.5, 1, and 3 wt.%. We employed a two-step fabrication process to ensure an even mixture and distribution of the rGO sheets within the PCL matrix. The inks were prepared by creating composite PCL-rGO films through solvent evaporation casting that were subsequently fed into the 3D printer for extrusion. The resultant scaffolds were seamlessly integrated, and 3D printed with high fidelity and consistency across all groups. This, together with the homogeneous dispersion of the rGO sheets within the polymer matrix, significantly improved the compressive strength and stiffness by 185% and 150%, respectively, at 0.5 wt.% rGO inclusion. The in vitro response of the scaffolds was assessed using human adipose-derived stem cells. All scaffolds were cytocompatible and supported cell growth and viability. These mechanically reinforced and biologically compatible 3D printed PCL-rGO scaffolds are a promising platform for regenerative engineering applications.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33335152 PMCID: PMC7747749 DOI: 10.1038/s41598-020-78977-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Steps involved in fabricating the composite PCL-rGO 3D printed scaffolds. First, PCL was combined with rGO and vortexed until a homogenous dispersion was achieved. The suspension was then casted into films and the solvent was allowed to evaporate. The collected films were subsequently lyophilized and cut into small pellets to be fed into the 3D printer’s cartridge. Structures of two different thicknesses were 3D printed at a high-temperature and subsequently punched into scaffolds for further assessments. An optical image of the final 3D printed PCL-rGO structure is presented.
Figure 2Morphological evaluation of the scaffolds. (a) Images taken using the 3D printer’s CCD-camera of each deposited layer during the printing process. (b,c) SEM images of the 3D printed scaffolds taken from a (b) top-view at different magnifications and (c) cross-sectional view.
Figure 3Dimensional characterization of the 3D printed PCL-rGO scaffolds. (a) A schematic of the 3D printed structures describing the structure pattern, strand diameter, and pore size from two fields of view. (b) A representative image of the measurement process in using the ImageJ macro code. The yellow lines represent the borders of the strands and the green lines represent the borders of the pore areas. The dashed red line indicates the average angle of each strand or pore area. The yellow or green perpendicular line is a representative line of the width that is measured specifying the strand diameter or pore size, respectively. (c) The measured strand diameters and pore sizes in comparison to their respective theoretical values. Results are presented as mean ± SD.
Figure 4Compositional characterization of the 3D printed scaffolds. (a) The TGA thermograms of the 3D printed scaffolds. (b) The enlarged region of the TGA thermograms indicating the remaining mass in each sample. (c) The TGA first derivative curves of the 3D printed scaffolds. (d) The XRD patterns of non-porous 3D printed scaffolds and pure rGO.
Figure 5Characterization of the hydrophilicity and in vitro biodegradation behavior of the scaffolds. (a) The contact angle images and measurements of the scaffolds with different concentrations of rGO. Results are presented as mean ± SD (n = 5). (b,c) The in vitro degradation behavior of the 3D printed scaffolds after incubation in SBF over the course of 14 days and under physiological conditions. The (b) swelling rate and (c) weight loss of the scaffolds expressed in % and presented as mean ± SD (n = 3) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Figure 6Mechanical analysis of the 3D printed scaffolds. (a) The representative stress–strain curves of the 3D printed scaffolds under uniaxial compression loading. (b) The compressive moduli and (c) compressive strength of the 3D printed scaffolds. Results are presented as mean ± SD (n = 4) (****p < 0.0001).
Figure 7Sub-nanometer level structural analysis of the 3D printed PCL-rGO scaffolds. (a) The WAXS patterns of the 3D printed scaffolds. (b) The enlarged region of the WAXS pattern indicating the characteristic peak of graphite which corresponds to the aggregation and re-stacking of the graphenic layers.
Figure 8Cytocompatibility of the 3D printed scaffolds. (a) Representative confocal micrographs of hADSCs grown on the 3D printed scaffolds and stained with the fluorescent live/dead assay (green, calcein AM; red, ethidium homodimer-1). The strand borders are identified using dashed lines (scale bar 200 μm). (b) Cell viability of hADSCs on the 3D printed scaffolds, measured by the MTS assay. Results are expressed as % viability with respect to the PCL control at each time point and are presented as mean ± SD (n = 3) (*p < 0.05, **p < 0.01).